Results 41 to 50 of about 13,155 (273)

DmCatD, a cathepsin D-like peptidase of the hematophagous insect Dipetalogaster maxima (Hemiptera: Reduviidae): Purification, bioinformatic analyses and the significance of its interaction with lipophorin in the internalization by developing oocytes [PDF]

, 2018
DmCatD, a cathepsin D-like peptidase of the hematophagous insect Dipetalogaster maxima, is synthesized by the fat body and the ovary and functions as yolk protein precursor. Functionally, DmCatD is involved in vitellin proteolysis.
Arrese, Estela L., Canavoso, Lilian Etelvina, Carlini, Célia Regina R S, Defferrari, Marina S., Fruttero, Leonardo Luis, Leyria, Jimena, Ligabue Braun, Rodrigo, Settembrini, Beatriz Patricia, Soulages, José L.   +8 more
core   +1 more source

Research advances in targeted protein degradation technologies [PDF]

Yixue xinzhi zazhi
Targeted protein degradation (TPD) technologies leverage the body’s innate protein degradation systems to selectively eliminate protein of interest (POI).
PI Chuan, HAO Xuanrun, XIAO Haiting, LUO Xing, ZHANG Qixiong   +4 more
doaj   +1 more source

Caspase-7 uses an exosite to promote poly(ADP ribose) polymerase 1 proteolysis [PDF]

, 2012
During apoptosis, hundreds of proteins are cleaved by caspases, most of them by the executioner caspase-3. However, caspase-7, which shares the same substrate primary sequence preference as caspase-3, is better at cleaving poly(ADP ribose) polymerase 1 ...
Blais, Véronique, Boucher, Dave, Denault, Jean-Bernard   +2 more
core   +1 more source

PROTACs are effective in addressing the platelet toxicity associated with BCL-XL inhibitors

Exploration of Targeted Anti-tumor Therapy, 2020
BCL-XL is an anti-apoptotic protein that plays an important role in tumorigenesis, metastasis, and intrinsic or therapy-induced cancer drug resistance.
Peiyi Zhang, Xuan Zhang, Xingui Liu, Sajid Khan, Daohong Zhou, Guangrong Zheng   +5 more
doaj   +1 more source

BAF complex vulnerabilities in cancer demonstrated via structure-based PROTAC design [PDF]

, 2019
Targeting subunits of BAF/PBAF chromatin remodeling complexes has been proposed as an approach to exploit cancer vulnerabilities. Here, we develop proteolysis targeting chimera (PROTAC) degraders of the BAF ATPase subunits SMARCA2 and SMARCA4 using a ...
Arnhof, Heribert, Bader, Gerd, Boehmelt, Guido, Ciulli, Alessio, Dank, Christian, Diers, Emelyne, Ehrenhöfer-Wölfer, Katharina, Ettmayer, Peter, Farnaby, William, Galant, Michael, Gerstberger, Thomas, Gmaschitz, Teresa, Greb, Peter, Karolyi-Oezguer, Jale, Koegl, Manfred, McConnell, Darryl B., Owen-Hughes, Tom, Pearson, Mark, Petermann, Oliver, Riedmueller, Carina, Rinnenthal, Joerg, Roy, Michael J., Rumpel, Klaus, Schnitzer, Renate, Sharps, Bernadette, Steurer, Steffen, Trainor, Nicole, Traxler, Elisabeth, Wachter, Johannes, Weinstabl, Harald, Weiss-Puxbaum, Alexander, Whitworth, Claire, Wiechens, Nicola, Wu, Meng-Ying, Wöhrle, Simon, Zoephel, Andreas, Zollman, David   +36 more
core   +2 more sources

Proteolysis-Targeting Chimeras as Therapeutics and Tools for Biological Discovery [PDF]

Cell, 2020
New biological tools provide new techniques to probe fundamental biological processes. Here we describe the burgeoning field of proteolysis-targeting chimeras (PROTACs), which are capable of modulating protein concentrations at a post-translational level by co-opting the ubiquitin-proteasome system. We describe the PROTAC technology and its application
George M, Burslem, Craig M, Crews
openaire   +2 more sources

Minimal requirements for ubiquitination mediated regulation of thyroid hormone activation [PDF]

, 2014
Activation of thyroxine by outer ring deiodination is the crucial first step of thyroid hormone action. Substrate-induced ubiquitination of type 2 deiodinase (D2) is the most rapid and sensitive mechanism known to regulate thyroid hormone activation ...
Egri, Péter, Gereben, Balázs
core   +1 more source

Proteolysis-targeting chimera against BCL-XL destroys tumor-infiltrating regulatory T cells

Nature Communications, 2021
Targeting regulatory T cells (Treg) represents a therapeutic option to abrogate tumor-associated immune suppression. Here the authors show that pharmacological degradation of BCL-XL preferentially induces apoptosis of tumor-infiltrating Treg, promoting ...
Ryan Kolb, Umasankar De, Sajid Khan, Yuewan Luo, Myung-Chul Kim, Haijun Yu, Chaoyan Wu, Jiao Mo, Xin Zhang, Peiyi Zhang, Xuan Zhang, Nicholas Borcherding, Daniel Koppel, Yang-Xin Fu, Song Guo Zheng, Dorina Avram, Guangrong Zheng, Daohong Zhou, Weizhou Zhang   +18 more
doaj   +1 more source

Development of KEAP1-targeting PROTAC and its antioxidant properties: In vitro and in vivo

Redox Biology, 2023
Oxidative stress due to abnormal accumulation of reactive oxygen species (ROS) is an initiator of a large number of human diseases, and thus, the elimination and prevention of excessive ROS are important aspects of preventing the development of such ...
Se Yong Park, Raju Gurung, Jung Ho Hwang, Ju-Hee Kang, Hyun Jin Jung, Alam Zeb, Jong-Ik Hwang, Sung Jean Park, Han-Joo Maeng, Dongyun Shin, Seung Hyun Oh   +10 more
doaj   +1 more source

Bridged Proteolysis Targeting Chimera (PROTAC) Enables Degradation of Undruggable Targets. [PDF]

J Am Chem Soc, 2022
Proteolysis Targeting Chimeras (PROTACs) are attractive therapeutic modalities for degrading disease-causing proteins. While many PROTACs have been developed for numerous protein targets, current small-molecule PROTAC approaches cannot target undruggable proteins that do not have small-molecule binders.
Xiong Y, Zhong Y, Yim H, Yang X, Park KS, Xie L, Poulikakos PI, Han X, Xiong Y, Chen X, Liu J, Jin J.   +11 more
europepmc   +3 more sources